Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

20250 citationsJournal Articlehybrid Open Access

Authors

Mark S. Shahin

Raina Mathur

Anju Parthan

Prakirthi Yerram

Amanda Kesner-Hays · Corcept Therapeutics (United States)

Rachel Myers

Iulia Cristina Tudor · Corcept Therapeutics (United States)

Darin Dobler · Corcept Therapeutics (United States)

Adrian M. Jubb · Corcept Therapeutics (United States)

Abstract

Nab-paclitaxel demonstrated comparable effectiveness to paclitaxel with a lower rate of peripheral neuropathy, suggesting that nab-paclitaxel is an effective treatment option and a relevant comparator for clinical trials of patients with PROC.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Cancer Treatment and Pharmacology

Publication Details

Published in: Gynecologic Oncology

Volume 204, pp. 202-209

DOI: 10.1016/j.ygyno.2025.11.022

Field-Weighted Citation Impact: 0.00

Command Palette

Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

Authors

Abstract

Topics & Keywords

Publication Details